htp

In vitro display technologies enable protein and antibody selection. Biointron highlights methods like phage, yeast, and ribosome display that drive discovery.

High-throughput antibody expression drives speed and scale. Biointron applies automated platforms to deliver reproducible antibodies for research and therapy.

Analytical tools define antibody quality. Biointron applies SPR, BLI, and mass spectrometry to deliver precise characterization and support therapeutic success.

Biointron's SVP of R&D, Lei Shi, PhD, discussed the processes of accelerating early discovery through HTP and high-speed antibody production during the Antibody Engineering & Therapeutics US 2023 conference in San Diego. Below is a summary of the talk.

Therapeutic antibody discovery begins with screening. Biointron applies ELISA, SPR, and AI-driven tools to identify high-affinity antibodies with precision and speed.